The Pharma Data

DECEMBER 2, 2020

She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley. Enthera’s discovery engine and assets are protected by a broad portfolio of patents. Source link.

Pharmaceuticals

Codon

APRIL 2, 2024

A gene encoding green fluorescent protein was placed alongside one of the three promoters, and as the engineered cells cycled from one gene to the next, they blinked between green—dark—green—dark. These papers became the standard-bearers for a new scientific field: synthetic biology. Elowitz: I always liked the term.

RNA

Dark Matter Blog

APRIL 8, 2020

Most people, and in particular most investors we spoke to in those early days, thought we were nuts – that RNA lacked the structural and molecular complexity that medicinal chemistry exploits with such great effect for proteins. One is that molecular recognition is purely a matter of physics and RNA has to play by the same rules.

RNA